Oral Delivery of Antidiabetic Polypeptide-k: Journey so far and the Road Ahead.

Kaur, P; Garg, V; Gulati, M; Singh, SK

Oral Delivery of Antidiabetic Polypeptide-k: Journey so far and the Road Ahead.

Kaur, P Garg, V Gulati, M Singh, SK

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: Curr Drug Deliv, 2016, 13, (2), pp. 236-244
Issue Date:: 2016

Closed Access

	Filename	Description	Size
	19406310_8536942170005671.pdf	Published version	2.34 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kaur, P
dc.contributor.author	Garg, V
dc.contributor.author	Gulati, M
dc.contributor.author	Singh, SK
dc.date.accessioned	2022-08-17T19:57:54Z
dc.date.available	2015-10-08
dc.date.available	2022-08-17T19:57:54Z
dc.date.issued	2016
dc.identifier.citation	Curr Drug Deliv, 2016, 13, (2), pp. 236-244
dc.identifier.issn	1567-2018
dc.identifier.issn	1875-5704
dc.identifier.uri	http://hdl.handle.net/10453/160438
dc.description.abstract	The prevalence of diabetes mellitus is growing rapidly. According to the global report of International Diabetes Fedration (IDF), about 382 million people are suffering from diabetes and among them, 90% cases were of type-II. By 2035, it is expected that this number will reach to 592 million. In the last 5 decades, various efforts have been put towards the development of synthetic medicines or synergistic combination of herbal and synthetic medicines to treat diabetes mellitus. Polypeptide-k is an antihyperglycaemic protein isolated from dried seeds collected from ripened fruits of Momordica charantia. Extensive research has been carried out in the last fifteen years on polypeptide-k to explore its potential applications for the treatment of both types of diabetes mellitus. This review highlights the available marketed formulations and research investigations conducted on humans to prove the potential of polypeptide-k as an antihyperglycaemic agent. This article also marks the reasons and need for oral delivery of polypeptide-k.
dc.format	Print
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	Curr Drug Deliv
dc.relation.isbasedon	10.2174/1567201812666151012113221
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.mesh	Administration, Oral
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Humans
dc.subject.mesh	Hypoglycemic Agents
dc.subject.mesh	Momordica charantia
dc.subject.mesh	Peptides
dc.subject.mesh	Plant Preparations
dc.subject.mesh	Seeds
dc.subject.mesh	Humans
dc.subject.mesh	Momordica charantia
dc.subject.mesh	Seeds
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Peptides
dc.subject.mesh	Plant Preparations
dc.subject.mesh	Hypoglycemic Agents
dc.subject.mesh	Administration, Oral
dc.title	Oral Delivery of Antidiabetic Polypeptide-k: Journey so far and the Road Ahead.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	United Arab Emirates
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
dc.date.updated	2022-08-17T19:57:52Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	13
utslib.citation.issue	2

Abstract:

The prevalence of diabetes mellitus is growing rapidly. According to the global report of International Diabetes Fedration (IDF), about 382 million people are suffering from diabetes and among them, 90% cases were of type-II. By 2035, it is expected that this number will reach to 592 million. In the last 5 decades, various efforts have been put towards the development of synthetic medicines or synergistic combination of herbal and synthetic medicines to treat diabetes mellitus. Polypeptide-k is an antihyperglycaemic protein isolated from dried seeds collected from ripened fruits of Momordica charantia. Extensive research has been carried out in the last fifteen years on polypeptide-k to explore its potential applications for the treatment of both types of diabetes mellitus. This review highlights the available marketed formulations and research investigations conducted on humans to prove the potential of polypeptide-k as an antihyperglycaemic agent. This article also marks the reasons and need for oral delivery of polypeptide-k.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160438